-

Ionis to host investors and analysts for Innovation Day 2025

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that it will host Ionis Innovation Day on Tuesday, October 7, 2025, in New York.

The agenda will feature presentations from members of the Ionis leadership team as well as a key thought leader in the treatment of severe hypertriglyceridemia, familial chylomicronemia syndrome and lipid disorders, Robert D. Fishberg, M.D., cardiologist with Atlantic Medical Group in Springfield, NJ, and assistant clinical professor of medicine at the Sidney Kimmel Medical College, Thomas Jefferson University. The presentations will be webcast live from 8:30 a.m. to 12:30 p.m. Eastern time.

Please click here to register for the event.

A webcast replay will be available for a limited time at the Investor Events section of Ionis’ website.

About Ionis Pharmaceuticals, Inc.

For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has marketed medicines and a leading pipeline in neurology, cardiometabolic disease and select areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about Ionis, visit Ionis.com and follow us on X (Twitter), LinkedIn and Instagram.

Contacts

Ionis Pharmaceuticals Investor Contact:
D. Wade Walke, Ph.D. – IR@ionis.com – 760-603-2331

Ionis Pharmaceuticals Media Contact:
Hayley Soffer – media@ionis.com – 760-603-4679

Industry:

Ionis Pharmaceuticals, Inc.

NASDAQ:IONS
Release Versions
English

Contacts

Ionis Pharmaceuticals Investor Contact:
D. Wade Walke, Ph.D. – IR@ionis.com – 760-603-2331

Ionis Pharmaceuticals Media Contact:
Hayley Soffer – media@ionis.com – 760-603-4679

More News From Ionis Pharmaceuticals, Inc.

Ionis to present new data supporting DAWNZERA™ (donidalorsen) in hereditary angioedema at 2026 AAAAI Annual Meeting

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced new data to be presented for DAWNZERA™ (donidalorsen), the first and only RNA-targeted medicine for hereditary angioedema (HAE), including new analyses from the Phase 3 OASIS-HAE and OASISplus studies. Results will be presented at the 2026 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in Philadelphia, PA. “These data add to a growing body of evidence outlining the clinical...

Olezarsen sNDA accepted by the FDA for Priority Review for the treatment of severe hypertriglyceridemia (sHTG)

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for olezarsen for severe hypertriglyceridemia (sHTG). The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of June 30, 2026. “Current standard of care therapies for sHTG provide limited benefit, leaving people vulnerable to recurrent and debilitating acut...

Ionis reports fourth quarter and full year 2025 financial results and highlights progress on key programs

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the “Company”) today reported financial results and provided key updates for the fourth quarter and year ended December 31, 2025. "2025 was a defining year for Ionis, marked by the successful execution of our first two independent launches and multiple positive data readouts across our pipeline, positioning Ionis for continued success in 2026,” said Brett P. Monia, Ph.D., chief executive officer of Ionis. “This year,...
Back to Newsroom